bioihbjkbjnl/mcl2 huggingface dataset:
Acute Responses of Postural Alignment, Kinematic Synergy, and Intermuscular Coherence to Postural Muscle Facilitation (Retrospective)
Condition: Posture; Musculoskeletal Equilibrium
Study type: Interventional

Summary: 
      Postural alignment is often intervened upon in health, fitness, and physical medicine
      settings. Despite a long tradition in this area, current notions of optimal or normal posture
      are superficial and often logically inconsistent. A recent attempt to reconcile diverging
      opinions about good posture proposes that alignment be considered in relation to individual
      joints' natural tendencies to collapse under gravity. This theory allows different
      maladaptive postures to be described in terms of functional deficits and compensatory
      adaptations at the muscular level. Working within this type of theory, postural interventions
      may be able to account for comparative advantages in maintaining alignment between different
      muscle systems. This would represent a step forward from current practices, which usually
      attempt to force arbitrary alignment patterns indiscriminately.

      The current study presents motion capture and electromyography (EMG) data evaluating the
      effects of two interventions on individual participants' bipedal standing alignment patterns
      with respect to the gravitational collapsing tendencies referenced above. Additional outcomes
      included functional grouping of muscle activation signals (via intermuscular coherence) and
      kinetic chain continuity. The interventions include 1) an experimental intervention purported
      to engage muscles that naturally resist the collapsing effects of gravity, and 2) a control
      intervention designed to inhibit other muscle groups that are sometimes involved in
      maintaining bipedal alignment in a compensatory role. Study outcomes are measured before and
      after both interventions to quantify the acute effects of each. All participants complete
      both interventions in random order, crossing over after a one-week washout period. This
      research will provide insight into the acute effects of studied interventions, specifically
      those relating to maintenance of bipedal alignment with respect to gravitational collapsing
      tendencies.
    


Intervention name(s): Exercise Then Foam Roll; Foam Roll Then Exercise
Intervention type(s): Other; Other
Intervention description(s): Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.; Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
Other intervention name(s): AB; BA
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Effects of A2 Milk on Gastrointestinal Function in Non-lactose Milk Intolerance
Condition: Milk Intolerance
MeSH terms: Lactose Intolerance
Study type: Interventional

Summary: 
      There is increasing evidence that a number of people experience moderate milk intolerance
      characterised by increased gas production, bloating and abdominal cramp, which can neither be
      attributed to lactose intolerance, nor to milk protein allergy. Milk digestion can lead to
      the formation of bioactive peptides, one of which derived from a mutated gene variant (A1)
      coding for milk beta-casein has been associated with increased gastrointestinal inflammation
      and poor gastrointestinal function. In this study, we hypothesise that consumption of
      non-mutated A2 milk will improve gastrointestinal symptoms in non-lactose milk intolerant
      individuals.
    

Detailed description: 
      Non-lactose milk intolerance is a condition that has not been defined clinically yet but the
      current literature reports existence of subjects who are moderately milk intolerant and whose
      intolerance can neither be attributed to a defect in lactose intolerance, nor to milk protein
      allergy. Yet, they experience at least one or two of the following symptoms following milk
      consumption: gases, bloating, abdominal cramp. It is known that the A1gene variant coding for
      beta-casein leads to the production of a bioactive peptide with opioid activity named
      betacasomorphin 7 (BCM7). This peptide has been associated with several metabolic health
      disorders including diabetes, elevated cardiovascular risk and stimulation of
      pro-inflammatory signals. Recently, it was reported that non-lactose milk intolerant subjects
      did not experience such symptoms when consuming milk containing the non-mutated A2 gene
      variant coding for beta-casein. In this study, we hypothesise that consumption of A2 milk
      will improve gastrointestinal symptoms in non-lactose milk intolerant individuals. The
      primary outcome of this study will be the reduction of gastrointestinal inflammation
      following a course of A2 milk consumption.
    

Intervention name(s): A2 milk 100; A2 milk 150; A2 milk 200; A2 milk 250; A1/A2 milk 100; A1/A2 milk 150; A1/A2 milk 200; A1/A2 milk 250
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement; Dietary Supplement; Dietary Supplement; Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): Days 1 and 2: 100 mL A2 milk twice a day; Days 3 and 4: 150 mL A2 milk twice a day; Days 5 and 6: 200 mL A2 milk twice a day; Days 7 to 14: 250 mL A2 milk twice a day; Days 1 and 2: 100 mL A1/A2 milk twice a day; Days 3 and 4: 150 mL A1/A2 milk twice a day; Days 5 and 6: 200 mL A1/A2 milk twice a day; Days 7 to14: 250 mL A1/A2 milk twice a day
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Basic Science
Participant(s) With Autism and High Pain Tolerance Treated With High Dose Naltrexone
Condition: Autism Spectrum Disorder
MeSH terms: Autistic Disorder; Autism Spectrum Disorder
Study type: Observational

Summary: 
      High dose naltrexone with response gauged by pain tolerance as measured by the cold pressor
      test may help treat autism.
    

Detailed description: 
      Clinical Trial: Cause and Treatment of High Opioid Tone Autism Key Words: autism,
      neurobiological systems engineering, opioid tone, cold pressor time, clinical trial Abstract
      Introduction: Neurobiological systems engineering models are useful for treating patients. We
      show a model of "high opioid tone" autism and present a hypothesis about how autism is caused
      by administration of opioids during childbirth.

      Main Symptoms: Clinical diagnosis of autism in a 25 year old man was confirmed by a Social
      Responsiveness Scale (SRS) self - rating of 79, severe, and a Social Communications
      Questionnaire (SCQ - 2) by the patient's father scoring 27. Cold pressor time is a measure of
      pain tolerance obtained by having the subject submerge their normal forearm in a painful ice
      water bath. Cold pressor time (CPT) was 190 seconds - unusually long, consonant with the high
      pain tolerance of autism.

      Therapeutic Intervention and Outcome Measure:

      Primary Outcome Measure is the Cold Pressor Time (CPT). At naltrexone 50 mg/day CPT fell to
      28, repeat 39 seconds.

      Secondary outcome measures are Social Responsiveness Scale (SRS) and Social Communications
      Questionnaire (SCQ-2). SRS fell to 54 and SCQ - 2 to 9; both non - significant for autism.

      Change in relatedness was experienced ambivalently, understood as feelings never before
      experienced - causing pain. Non - compliance with naltrexone was followed by cutting open his
      palm and drinking alcoholically. Transference focused psychotherapy has helped him remain
      naltrexone - compliant while he works on issues of identity and relatedness.

      Conclusion: The model suggests studies that could be conducted to both prevent and treat this
      form of autism.
    

Intervention name(s): 50 mg naltrexone
Intervention type(s): Drug
Intervention description(s): Medication combined with twice a week psychotherapy
Intervention MeSH terms: Naltrexone
Observational model: Case-Only
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Adolescents and adults with autism spectrum disorder
Vitamin D Deficit in Women With Uterine Fibroids
Condition: Leiomyoma; Vitamin D Deficiency; Fibroid Uterus
MeSH terms: Leiomyoma; Myofibroma; Vitamin D Deficiency
Study type: Observational

Summary: 
      Determinate the level of vitamin D in blood, and evaluate the prevalence of deficit and
      insufficiency among patients with diagnosis of uterine fibroids
    

Detailed description: 
      A cross-sectional prevalence study will be carried out, taking patients with a diagnosis of
      uterine fibroid in two hospitals; blood level of vitamin D will be taken to determine the
      proportion of patients with deficit and insufficiency; In addition, the number, size and type
      (according to the PALM-COEN classification) of the uterine fibroids in each patient will be
      analyzed.
    

Intervention name(s): Level of Vitamin D
Intervention type(s): Diagnostic Test
Intervention description(s): 3 ml of venous blood will be taken to determine the level of vitamin D
Intervention MeSH terms: Vitamin D
Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        All female patients diagnosed with uterine myomatosis who come for consultation, if they
        agree to be part of protocol, an informed consent will be given and a 3 ml sample of venous
        blood will be taken.

        The present study will be performed in two Hospitals:

        "Centro Médico Nacional de Occidente" (CMNO) "Hospital General Regional No. 45" (HGR 45)
        Both hospital established in the city of Guadalajara, Jalisco, Mexico.
      
Biospecimen description: 
      3 ml of venous blood sample to determine levels of vitamin D
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
Condition: Essential Hypertension
MeSH terms: Hypertension; Essential Hypertension
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate the efficacy and safety of various dosage
      combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with
      their respective components and with placebo.
    


Intervention name(s): Placebo; Lercanidipine; Lercanidipine; Enalapril; Enalapril; Lercanidipine + Enalapril; Lercanidipine + Enalapril; Lercanidipine + Enalapril; Lercanidipine + Enalapril
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): once daily for 10 weeks; 10 mg once daily for 10 weeks; 20 mg once daily for 10 weeks; 10 mg once daily for 10 weeks; 20 mg once daily for 10 weeks; 10/10 mg once daily for 10 weeks; 10/20 mg once daily for 10 weeks; 20/10 mg once daily for 10 weeks; 20/20 mg once daily for 10 weeks
Intervention MeSH terms: Enalapril; Enalaprilat; Lercanidipine
Allocation: Randomized
Intervention model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Hypertension; Lercanidipine; Calcium antagonist; Enalapril
A Study of OV101 in Individuals With Fragile X Syndrome
Condition: Fragile X Syndrome (FXS)
MeSH terms: Fragile X Syndrome; Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101
      (gaboxadol) in subjects with Fragile X syndrome.
    


Intervention name(s): OV101 (gaboxadol)
Intervention type(s): Drug
Intervention description(s): OV101 (gaboxadol)
Intervention MeSH terms: Gaboxadol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease
Condition: Kawasaki Disease
MeSH terms: Mucocutaneous Lymph Node Syndrome
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of this study is to evaluate the safety, efficacy and of Immune Globulin
      Intravenous (Human) IVIG-SN™ in subjects with kawasaki diseases.
    

Detailed description: 
      This clinical trial was designed as a multicenter, single-arm, and open-label clinical trial.

      Evaluate the incidence of coronary artery lesions in the 7th week of IVIG-SN administration,
      compared to the incidence of coronary artery lesions among untreated Kawasaki patients, to
      prove the superior efficacy of IVIG-SN.
    

Intervention name(s): immunoglobulin G
Intervention type(s): Drug
Intervention description(s): Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
Intervention MeSH terms: Immunoglobulins; Immunoglobulins, Intravenous; Antibodies; Immunoglobulin G
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional

Summary: 
      Telehealth remote patient monitoring is a means of using communications technology - such as
      telephones, computers, and the Internet - to connect patients remotely with their healthcare
      team from their homes. The investigators hope to learn more about improving healthy behaviors
      and blood glucose among persons with diabetes using telehealth remote patient monitoring
      technology to connect directly with nurse care coordinators.

      The purpose of this study is to evaluate a process for improving blood glucose and healthy
      behaviors among people with type 2 diabetes using telehealth remote patient monitoring
      technology with nurse care coordinators. Some of the people in this study will work with a
      nurse care coordinator who will review your blood glucose weekly and call you at home every
      month for 3 months, while some of the people in this study will simply receive their normal
      care. At the end of the study, every participant will be asked questions about how they feel
      about their health care.
    


Intervention name(s): Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
Intervention type(s): Behavioral
Intervention description(s): In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Type 2 diabetes; self-management; remote patient monitoring
Knowledge Assessment of Women About Pictograms Associated With the Danger of Medicines Taken During Pregnancy
Condition: Knowledge, Attitudes, Practice; Pregnancy Related
Study type: Observational

Summary: 
      Women's awareness about the danger of certain medicines taken during pregnancy presents a
      real public health issue. To enhance awareness and information for women and healthcare
      professionals, new pictograms " pregnant women " appeared on medication boxes, on October 16,
      2017. These new pictograms can change women's perception of self-medication during pregnancy
      and of the danger of taking certain medicines for the unborn development. Furthermore, the
      investigators can wonder if the meaning of these pictograms is well understood. Therefore,
      the study's primary aim is to assess the knowledge of pregnant or childbearing age women
      about the pictograms associated with the danger of certain medicines taken during pregnancy.
    


Intervention name(s): questionary
Intervention type(s): Behavioral
Intervention description(s): A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.
Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally.
Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        pregnant or childbearing age women between 18 and 45 years old.
      
Keywords: knowledge; medicine; pictogram; pregnant woman; childbearing age woman
Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Condition: HIV Infections
MeSH terms: HIV Infections
Study type: Interventional
Phase: Phase 1

Summary: 
      24 healthy male and female volunteers who are at low risk of HIV infection and entered into
      the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of MVA-B
      at weeks 0, 4 and 16 will receive a boosting dose 4 years thereafter.

      Participants will attend one of two clinical centres on at least 5 occasions over 16 weeks.
      These visits will comprise:

        -  Screening

        -  Trial entry and boosting immunisation

        -  Early follow-up after immunisation

        -  Follow-up x 2 including the final visit Participants will have blood and urine
           collected, and receive 1 immunisation. They will be counselled prior to and following a
           HIV test, and given health education on prevention of sexually transmitted infections
           including HIV. T

      The two centres which participate are:

        -  Hospital Clinic, Barcelona and

        -  Hospital Gregorio Marañón, Madrid The primary objective is to explore the safety and
           immunogenicity of MVA-B.
    


Intervention name(s): Experimental
Intervention type(s): Biological
Intervention description(s): Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Low risk HIV infection; HIV Seronegativity; HIV Preventive Vaccine
Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness
Condition: Motion Sickness
MeSH terms: Motion Sickness
Study type: Interventional
Phase: Phase 4

Summary: 
      This is an open-label, case control study of 180 patients presenting motion sickness, who
      will perform a motion sickness assessment questionnaire before and after treatment with dry
      ginger (Z. officinale) extract.
    

Detailed description: 
      This open-label, self-paired, case-control study will evaluate 180 patients presenting motion
      sickness. The primary study objective is to evaluate the use of dry Z. officinale extract
      160mg (containing 8mg gingerol) in the treatment of patients presenting motion sickness. The
      secondary objectives are to evaluate the effect of the treatment on the scores and subscores
      of the Motion Sickness Assessment Questionnaire (MSAQ) before and after treatment, as well as
      to assess treatment tolerability in this population. The total study duration will be seven
      days. A total of four specific motion sickness assessments will be performed, one
      pre-treatment and three during the treatment period, which consists of an oral dose of 160mg
      ginger extract 30 minutes prior to the trip under evaluation.
    

Intervention name(s): Z. officinale extract
Intervention type(s): Drug
Intervention description(s): Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
Intervention model: Single Group Assignment
Intervention model description: Open-label, single-group, self-paired study
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Zingiber officinale; Motion sickness; Motion sickness assessment questionnaire
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
Condition: Cholangiocarcinoma, Intrahepatic; Recurrence Cholangiocarcinoma; Re-hepatectomy
MeSH terms: Cholangiocarcinoma; Recurrence
Study type: Observational

Summary: 
      The investigators retrospectively reviewed the participants suffering from recurrent
      intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive
      factors for recurrence and clarify the potential benefit of repeat hepatectomy or/with
      metastasectomy.
    


Intervention name(s): hepatectomy
Intervention type(s): Procedure
Intervention description(s): Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
Observational model: Case-Control
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Between January 1977 and December 2014, 452 patients underwent curative-intent, different
        extent of hepatectomy for ICC in the Department of General Surgery, Chang Gung Memorial
        Hospital, Linkou branch, Taiwan. Only 216 patients fulfilled selection criteria
        aforementioned.
      
Keywords: Recurrent intrahepatic cholangiocarcinoma; Intrahepatic cholangiocarcinoma; Repeat hepatectomy; Metastasectomy